MedPath

RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest

Phase 4
Not yet recruiting
Conditions
Heart Arrest
Interventions
Drug: physiological saline
Drug: Levosimendan Injection
Registration Number
NCT05956431
Lead Sponsor
Peking University Third Hospital
Brief Summary

This study is intended to use a multicenter, double-blind, superior effect, placebo controlled randomized controlled clinical trial to explore the therapeutic effect of Levosimendan (within 6 hours after the recovery of spontaneous circulation) on mortality and multiple organ dysfunction such as heart and brain in patients with cardiac arrest who have recovered from active Cardiopulmonary resuscitation but have low cardiac output syndrome and coma, and the impact of 30-day mortality and neurological function after cardiac arrest.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • 1: Age>18 years old

    2: After active Cardiopulmonary resuscitation, patients with cardiac arrest obtain the recovery of spontaneous circulation (ROSC), which is defined as having palpable arterial pulse lasting for more than 20 minutes

    3: Patients with witnessed cardiac arrest

    4: ROSC lasts for less than 60 minutes

    5: Low cardiac output syndrome after ROSC (LVEF<40%)

    6: Still in a coma after ROSC, Glasgow score<8 points

    7: Complete enrollment within 180 minutes after ROSC

Read More
Exclusion Criteria
  • 1: Patients receiving extracorporeal Cardiopulmonary resuscitation

    2: Patients with severe neurological deficits prior to cardiac arrest

    3: Patients with severe renal dysfunction (creatinine clearance rate<30ml/min)

    4: Patients with confirmed or suspected pregnancy

    5: Patients with Intracranial hemorrhage

    6: Patients with end-stage diseases, such as advanced malignant tumors or other severe wasting diseases

    7: Patients who are unwilling to participate in the study

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo groupphysiological salineThe placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
Levosimendan groupLevosimendan InjectionThe administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
Primary Outcome Measures
NameTimeMethod
Cerebral Performance Category (CPC)On the 30th day after cardiac arrest

The mortality rate and neurological prognosis at 30 days after cardiac arrest. The evaluation of neurological function adopts CPC score, with CPC 1-2 grading indicating a good prognosis for neurological function and CPC 3-5 grading indicating a poor prognosis for neurological function.

Secondary Outcome Measures
NameTimeMethod
Survival rateafter 1 week of resuscitation

Survival rate after 1 week of resuscitation was counted

EchocardiographyOn the first week after resuscitation

After enrollment, echocardiography parameters were collected according to the time nodes specified in this research process

Neuron-Specific Enolase (NSE)On the first week after resuscitation

After enrollment, NSE was collected according to the specified time points in this study process

Gray-to-White Matter Ratio (GWR)On the first week after resuscitation

After enrollment, head CT GWR were collected according to the specified time points in this study process

Serum creatinineOn the first week after resuscitation

After enrollment, serum creatinine indicators representing renal function were collected according to the specified time

© Copyright 2025. All Rights Reserved by MedPath